ASCO: Trametinib improves survival in metastatic melanoma
(HealthDay) -- For patients with metastatic melanoma with activating mutations in serine-threonine protein kinase B-RAF (BRAF), treatment with the oral selective MEK inhibitor trametinib is associated with improved progression-free ...
Jun 5, 2012
0
0